The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. MVI has licensed patented technologies from WARF, which were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/14 | $8,000,000 | Series A |
State of Wisconsin Investment Board Venture Investors Venture Management Wisconsin Alumni Research Foundation (WARF) | undisclosed |
